- Research article
- Open Access
Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology
© Ma et al.; licensee BioMed Central Ltd. 2012
Received: 4 June 2012
Accepted: 10 November 2012
Published: 21 November 2012
An antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used for clinical purposes. ERCC1 is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy. High ERCC1 expression is linked to drug resistance on cisplatin-based chemotherapy. 8F1 is one of the most commonly used monoclonal antibodies for evaluating ERCC1 expression levels in lung cancer patient tissues, but it has been noted that this antibody cross-reacts with an unknown protein.
By using a high density protein microarray chip technology, we discovered that 8F1 not only reacts with its authentic target, ERCC1, but also cross-reacts with an unrelated nuclear membrane protein, PCYT1A. The cross-reactivity is due to a common epitope presented on these two unrelated proteins. Similar to the subcellular localization of ERCC1, IHC tests demonstrated that PCYT1A is localized mainly on nuclear membrane. In this study, we also discovered that the PCYT1A gene expression level is significantly higher than the ERCC1 gene expression level in a certain population of lung cancer patient tissue samples. To develop the best monoclonal antibody for ERCC1 IHC analysis, 18 monoclonal antibodies were generated and 6 of them were screened against our protein microarray chip. Two clones showed high mono-specificity on the protein microarray chip test and both worked for the IHC application.
In summary, the 8F1 clone is not suitable for ERCC1 IHC assay due to its cross-reactivity with PCYT1A protein. Two newly generated monoclonal antibodies, 4F9 and 2E12, demonstrated ultra-specificity against ERCC1 protein and superior performance for IHC analyses.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. It accounts for more than 80% of all lung cancer related deaths . After surgical removal of NSCLC, cisplatin-based chemotherapy is the first line of treatment . Cisplatin and its derivatives are mutagenic chemicals that can induce DNA interstrand or intrastrand cross links through forming DNA adducts. Tumor cells damaged by these drugs will trigger cell death . However, cisplatin-based chemotherapy also causes highly toxic side effects [4–7]. Recent statistical analysis of clinical data shows that cisplatin-based chemotherapy can only add an approximately 4–15% survival advantage at five years with a subgroup of NSCLC patients exhibiting no beneficial effects of drug treatment or even worse outcomes after treatment [8, 9]. Thus, it is imperative to use prognostic or predictive biomarkers to identify patients who should receive cisplatin-based chemotherapy .
Cisplatin or other DNA crosslinkers could cause DNA damages on either one or two strands of DNA duplex. In cells, multiple DNA repair pathways are involved in repairing these damages, including nucleotide excision repair and interstrand crosslink repair pathway . Therefore, strong endogenous DNA damage repairing capabilities in tumor cells will compromise the therapeutic drug effects of cisplatin . This could be the major biochemical mechanism that explains different patient responses towards cisplatin-based treatments . The ERCC1-XPF heterodimeric endonuclease protein complex involves in both nucleotide excision repair and interstrand crosslink repair pathway. XPF acts as the catalytic subunit and ERCC1 binds DNA . Quite a number of clinical studies have already shown a good correlation between ERCC1 mRNA level and cisplatin drug resistance [15–17]. This suggests that examining ERCC1 expression levels might be a good method to identify patients who are likely to benefit from cisplatin-based chemotherapy.
To evaluate ERCC1 protein levels in formalin-fixed paraffin-embedded tissue samples, a high quality monoclonal antibody validated for immunohistochemistry is needed. Currently there are several anti-ERCC1 IHC antibodies available on the market [18, 19]. However, the published data for them is highly controversial and none of them is widely accepted as specific for application in IHC. More than 40 published clinical studies were conducted using the 8F1 clone making it the most commonly used anti-ERCC1 diagnostic monoclonal antibody currently on the market [20–24]. Recently, its target specificity has been questioned [19, 25]. By using an ERCC1-XPF deficient cell line, Bhagwat et al. discovered that the 8F1 antibody binds to an unknown cross-reactive protein that migrates at a molecular weight similar to ERCC1 on SDS-PAGE gels but the molecular identity for this cross-reactive target was unknown . In this paper, we describe the development and application of a high density protein microarray chip. With this technology, we were not only able to identify the molecular identity of 8F1 cross-reactive protein, but also able to use it as a tool to develop two highly specific monoclonal antibodies for ERCC1 IHC assay.
The high-throughput production of overexpression lysates from HEK293T cells transiently transfected with ORF cDNA expression clones
HEK293T cells from four fully confluent T150 tissue culture flasks were trypsinized and inoculated into 96 10 cm-tissue culture plates. After culturing for 24 hrs, cells were transiently transfected with 5ug of TrueORF cDNA plasmid per plate. After transfection, the cells were cultured at 37°C for another 48 hrs. Before cell lysate collection, transfected cells were washed once with 1xDPBS. Next, 800ul of freshly-prepared native RIPA lysis buffer (25 mM Tris-HCl pH7.6, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1xProtein inhibitor cocktail mix, 1 mM PMSF and 1 mM Na3VO4) is added directly to the cells and the plates were incubated on ice for 5 minutes to lyse the cells completely. The 96 crude cell lysates were transferred to a 96-deep well plate with 2 ml capacity (Axygen) and spun at 4000 x rpm to remove insoluble cellular debris. The clarified supernatants were transferred to a 96-well v-shape plate (BD) and stored at -80C for future protein microarray printing. The recombinant protein expression for every overexpression lysate used for microarray printing was validated by Western-blot analysis with the anti-DDK antibody (OriGene, TA50011-100).
Protein microarray printing
All overexpression lysates used for array printing were obtained from OriGene Technologies Inc. The detailed protocol for overexpression lysate production is described as above. Protein microarray printing was performed with QArray2 array printer (Genetix) with 48 5 um XSMP2 split pins. Grace Biolab Ovid 20X60 mm nitrocellulose slides were used for printing. The array contains a total of 22,176 spots with 10,464 lysates in duplicates (20,928 spots) and 1248 control spots. The whole slide is divided into 48 sub-arrays (4X12). For each subarray, 462 samples were spotted in 22X21 format. As an orientation marker control, each subarray contains an autofluorescent BSA-Cy5 and Cy3 mixture spot and a mixed IgG spot (mixture of human, mouse and rabbit IgGs). There are also additional sub-array controls including a buffer only negative control, a 1 mg/ml BSA control and a 1 mg/ml HEK293T lysate control. In addition to above subarray controls, we also added specific global positive and quantification controls. These controls include serially-diluted IgG mixture controls placed in sub-arrays C1, C5 and C9. As global negative control, serially diluted HEK293T lysates were spotted in subarrays A1, A5 and A9. Since every cDNA clone used for overexpression lysate production contains a DDK epitope tag, the recombinant protein expression level can be detected by using the 4C5 monoclonal anti-DDK antibody (TA50011-100, OriGene Technologies Inc.). Because the protein expression level for different genes varies greatly, two highly purified DDK fusion proteins were used as reference standards for the purpose of quantification. These two standards are GST and beta-actin. They are located either in subarray D1, D5 and D9 for GST or subarray B1, B5 and B9 for beta-actin.
Protein microarray immuno-hybridization assay
Before probing, the array chips were hydrated for at least 30 min in 10 ml distilled water followed by a 5 min equilibration with 5 ml wash buffer (20 mMTris, 150 mMNaCl, 0.05% Tween 20. pH 8.0).
Primary antibody was diluted to 5–10 μg/ml in 1 ml blocking buffer (StartingBlock T20 (TBS), Thermo) and added to the array in a ProPlate chamber (Grace-bio). The arrays were then incubated overnight at 5C with rocking. After overnight antibody incubation, arrays were washed briefly with 2 ml of wash buffer, transferred to Perfect Western 6-sectional short (B130) slide tray and then washed three times with 5 ml of wash buffer for 5 minutes each time.
DyLight 649-conjugated secondary antibody (Jackson Labs) was diluted 1:500 in wash buffer, added to the array slide, and then incubated for another 30 min at RT with rocking. After incubation, the stained arrays were washed extensively with distilled water and air-dried. The arrays were scanned with a Genepix 4100A scanner and data were analyzed using the appropriate gal file. The antibodies used for protein microarray chip analysis include rabbit polyclonal anti-ERCC1 (FL297) (Santa Cruz), anti-ERCC1 (8F1) (Abcam), and Anti-ERCC1 (4F9 and 2E12) (OriGene Technologies Inc.)
Tissue microarray production and Immunohistochemistry
The tissue microarray chip was generated using Sakura’s Tissue-Tek Quick-Ray system. On one slide, 12 human normal and 12 human carcinoma tissue samples were spotted. For immunohistochemical staining of the tissue-microarray chip and paraffin-embedded tissue sections, antigen retrieval was carried out in 0.01 M Sodium Citrate buffer at pH 6 in a pressure cooker for 2 minutes. Samples were blocked with 5% non-fat milk plus 5% goat serum for 30 min and then incubated with primary antibody at a 1:150 dilution for 60 min at room temperature. The primary antibody signal was detected using polink-2 anti-rabbit or anti-mouse secondary antibody for 30 min and DAB substrate for 5 min at room temperature (GBI Labs). Hematoxylin was used for counterstaining. The antibodies used for IHC analysis include anti-PCYT1A (EPR3940) (Epitomics), anti-ERCC1 (8F1) (Abcam), Anti-ERCC1 (4F9 and 2E12) (OriGene Technologies Inc.).
Quantitative real-time PCR
TissueScan 24 lung cancer panels (HLRT104, OriGene Technologies) were used to examine ERCC1 and PCYT1A mRNA expression profiles. The qPCR was performed on ABI 7900HT using the SYBR Green PCR Master Mix (Applied Biosystems). Primers used for ERCC1 mRNA detection were HP229725 with 5′-GCTGGCTAAGATGTGTATCCTGG-3′ (forward) and 5-ATCAGGAGGTCCGCTGGTTTCT-3 (reverse), for PCYT1A were HP208235 with 5′-GTTCCTTCCAAAGTGCAGCGCT-3′ (forward) and 5-AGGAGTTCCTCTGCTGGCTTCT-3, for β-actin were HP204660 with 5′-CAGCCATGTACGTTGCTATCCAGG-3′ (forward) and 5-AGGTCCAGACGCAGGATGGCATG-3 (OriGene Technologies Inc.). Relative quantification of ERCC1 and PCYT1A expression were measured by normalization against β-actin using the ΔCT method. The PCR efficiency values of E(ERCC1), E(PCYT1A) and E(β-actin)were determined using the copy number standards, HK202848, HK209617 and HK200550 respectively (OriGene Technologies Inc.).
Immunoblotting and recombinant protein affinity purification
For immunoblotting, overexpression lysates (OriGene Technologies Inc.) or purified proteins were mixed with 4XSDS sample buffer (Invitrogen), boiled for 5 minutes before loading on SDS-PAGE for fractionation. After separation on SDS-PAGE gel, they were electro-blotted on a nitrocellulose membrane. Anti-DDK (OriGene Technologies Inc.), anti-ERCC1 (8F1) (Abcam) or anti-ERCC1 (4F9 or 2E12) (OriGene Technologies Inc.) was used for immunoblotting.
For affinity purification of recombinant protein, HEK293T cells were first transiently transfected with an OriGene TrueORF cDNA clone (OriGene Technologies Inc.). After 48 hrs, transfected cells were collected and lysed with RIPA buffer (25 mM Tris-HCl pH7.6, 150 mM NaCl, 1% NP-40, 1xProtein inhibitor cocktail mix, 1 mM PMSF, 1 mM EDTA and 1 mM Na3VO4) and the cellular debris were removed by high speed centrifugation. For affinity purification, anti-DDK agarose beads were first balanced with RIPA buffer, and then added to pre-cleared overexpression lysates for overnight incubation. After incubation, the beads were extensively washed and purified proteins were eluted from the beads using a 0.1 M Glycine-HCl (pH2.3) solution.
Development of a high density overexpression lysate protein microarray chip for the evaluation of antibody specificity
Using a high density protein microarray chip to evaluate the target specificity of anti-ERCC1 monoclonal antibodies
To evaluate the 8F1 target specificity, this antibody was incubated at 5ug/ml concentration with the protein microarray chip. As suspected from Bhagwat et al, 8F1 not only reacts with its authentic target ERCC1 protein, but also binds strongly with an un-related nuclear protein, PCYT1A (see subarray 6B in Figure 2A). PCYT1A is an important enzyme in regulating phosphatidylcholine biosynthesis and nuclear membrane expansion . The functionality of this protein is actively regulated by a rapid translocation between a cytoplasmic soluble form that is inactive and a nuclear membrane-associated form that is activated . No published data show any correlation between PCYT1A expression levels and patient response to cisplatin-based chemotherapy.
Rabbit polyclonal antibody FL297 is another commonly used anti-ERCC1 IHC antibody. Studies from a number of groups suggested that the target specificity for FL297 could be considerably better than 8F1 under their IHC experimental conditions [18, 19, 28, 29]. To evaluate the specificity of this antibody, protein microarray chip hybridization and Western blot confirmation were performed. In comparison with the 8F1 monoclonal antibody, this rabbit antibody exhibits much broader cross-reactivity and higher background signals across the entire chip (see Additional file 1: Figure S1). On subarrays 2C and 2D, FL297 reacts with two ERCC1 recombinant protein isoforms encoded by two different transcript variants. However, it also shows strong cross-reactivity with two unrelated protein targets, PDK1 and FERMT3. This cross-reactivity was confirmed by WB analyses of PDK1 and FERMT3 overexpression lysates (Additional file 2: Figure S2). PDK1 is a central mediator of cellular signaling between PI-3 kinase and various intracellular serine/threonine kinases, including protein kinase B, p70 ribosomal S6 kinase, serum and glucocorticoid-inducible kinase, and protein kinase C. FERMT3 is a focal adhesion molecule implicated in integrin activation. So far there are no published results linking the protein or gene expression levels of either PDK1 or FERMT3 with the patient response to cisplatin-based chemotherapy. In terms of subcellular localization, neither of these two cross-reactive proteins is located in the nuclear region. These data are well correlated with previous observations that IHC immunostaining with FL297 shows some cytoplasmic staining .
Immunoassay analysis to confirm the protein microarray hybridization data with cross-reactive targets
To further confirm the protein microarray data, Western blot analyses were performed with OriGene’s VERIFY™ overexpression lysates. As negative controls, we included 4 different ERCC family members on the same WB to confirm the antibody specificity. Figure 2B is the representative WB data with clone 8F1 (Figure 2B upper panel). From this data, it is clear that 8F1 not only recognizes ERCC1 protein, but also PCYT1A strongly. No cross-reactivity was observed with other ERCC family members. The WB membrane was also re-blotted with anti-DDK antibody to confirm the expression of the different recombinant proteins for each of the input lysates (Figure 2B lower panel).
One possible explanation for this antibody cross-reactivity could be high sequence homology between its authentic target and the cross-reactive protein. To understand whether there is any amino acid sequence homology, we carried out an amino acid sequence alignment of ERCC1 and PCYT1A. No significant homology was detected (data not shown). However, it is possible that the epitope recognized by 8F1 is a discontinuous epitope and that a similar conformational epitope exists on PCYT1A because 8F1 was generated by using full length human recombinant ERCC1 protein as immunogen.
Monoclonal antibodies are produced by hybridoma cell lines, which are generated by the fusion between an antibody secreting B cell and a myeloma cell. Whether multiple B cells can fuse with one myeloma cell and produce different antibodies from a single hybridoma clone is still under-debate [30, 31]. If this does occur, it raises the possibility that multiple antibodies can be secreted from one hybridoma. Alternatively, hybridoma clone impurity could also attribute to the contamination of 8F1 antibody preparation. To evaluate contamination as the source of cross-reactivity, a set of immunogen absorption experiments were performed. As shown in Figure 3C, the immunoreactivities toward both PCYT1A and ERCC1 were ablated effectively after the pre-absorption with purified PCYT1A protein. However, no signal depletion was observed under the control experimental condition that used purified BSA protein as the negative control (data not shown). These data clearly demonstrate that a single 8F1 IgG molecule exhibits bi-specific binding capacity towards both ERCC1 and PCYT1A protein.
The immunohistochemical staining of NSCLC tissue sections with anti-ERCC1 and anti-PCYT1A monoclonal antibodies
ERCC1 protein is proposed as an important biomarker for clinicians to predict whether a certain patient population with non-small cell lung carcinoma (NSCLC) will respond to cisplatin chemotherapy . For pathological evaluation via the application of IHC analysis, nuclear immunostaining intensity is the critical measurement.
The 8F1 cross-reactive protein, PCYT1A, is a nuclear membrane protein. However, previous immunocytochemistry studies indicated that the subcellular localization for PCYT1A is dynamically regulated under different physiological conditions and it can switch between an inactive soluble or cytoplasmic form to an active, membrane-bound species within the nucleus . There are very few reports of immunohistochemistry analysis of PCYT1A protein in different tissues and those data are highly controversial .
To further survey the PCYT1A protein tissue expression profile, IHC analyses were performed on a tissue microarray slide containing 12 normal human tissue samples and 12 corresponding human tumor tissue samples. The IHC data with positive staining are shown in Additional file 3: Figures S3A and Additional file 4: Figure S3B. In summary, PCYT1A is primarily localized within nucleus under our current experimental conditions.
Comparison of ERCC1 and PCYT1A mRNA transcript levels by qPCR analysis on lung cancer patient tissue samples
Western blot analysis showed that there is no significant difference in terms of the binding efficiency for 8F1 to ERCC1 or to PCYT1A and our IHC data also demonstrated that ERCC1 and PCYT1A protein are colocalized within the nucleus compartment in NSCLC patient tissue samples. To facilitate our understanding of how much 8F1 nuclear immunostaining signal might be coming from 8F1-PCYT1A interaction, we wanted to compare the endogenous protein expression levels for PCYT1A and ERCC1 in lung cancer patients. However, the binding efficiency difference between each antibody-antigen pair would make it exceedingly difficult to estimate the endogenous protein expression level based on immunoassay data. Thus, we used a qPCR method to compare the endogenous expression at the mRNA level.
To examine the gene expression levels for ERCC1 and PCYT1A in different cancer patient tissue samples, we performed qPCR analysis on OriGene’s lung cancer qPCR TissueScan cDNA array panel, which contains cDNA from 24 lung cancer patient tissues. The final result is presented in Figure 5B. The majority of samples show that the mRNA expression level for ERCC1 is higher than that of PCYT1A. However, four lung cancer patient samples exhibited higher PCYT1A mRNA expression levels than ERCC1 mRNA expression. This clearly demonstrates that in a certain lung cancer patient population, a significant amount of 8F1 immunoreactive signal could come from the 8F1-PCYT1A interaction and argues against the use of the 8F1 clone for ERCC1 IHC diagnostic assays. It also highlights the need to generate a highly mono-specific monoclonal antibody for ERCC1 clinical applications.
Using a high density protein microarray chip to develop the most specific monoclonal anti-ERCC1 antibody for diagnostic IHC testing
To obtain highly mono-specific antibodies for ERCC1 IHC application, we used full-length human recombinant ERCC1 protein as the immunogen. This protein was purified from HEK293T cells that were transiently transfected with an ERCC1 cDNA clone (see Additional file 5: Figure S4 for coomassie staining of purified ERCC1). To ensure that we would generate the best IHC mAbs against ERCC1, we performed more than 8 fusions and got 18 positively validated hybridoma clones. All 18 mAbs were evaluated by Western-blotting the ERCC1 overexpression lysate and whole cell lysates of endogenous protein from 9 different cell lines. Our initial data showed that all 18 mAbs worked well with the ERCC1 overexpression lysate and four of them detected endogenous ERCC1 protein by Western blot with the cell line lysates (Additional file 6: Figures S5 and Additional file 7: Figure S6 show Western blot data for clones 4F9 and 2E12).
Immunohistochemistry (IHC) is a widely used antibody-based assay for pathologists to semi-quantitatively measure tumor biomarker expression. Due to the nature of IHC assay itself, the quality of IHC data depends heavily on the quality of the antibody. Therefore, to develop a validated IHC assay for clinical usage, the first step is to identify antibodies with the highest specificity on their authentic targets. Clinical studies have shown that the level of ERCC1 gene expression in cancer patients is correlated to drug resistance of cisplatin-based chemotherapy . Currently, there is no clinically approved ERCC1 IHC diagnostic assay available, likely due to the lack of a high quality anti-ERCC1 monoclonal antibody. Studies from a number of labs have shown that the 8F1 clone gives the best performance on NSCLC tissue in IHC assays [18, 34]. However, Bhagwat, et al. claimed that 8F1 is not mono-specific . By using an ERCC1 gene-ablated fibroblast cell line, they found that 8F1 can still binds to a specious immunoreactive band exhibiting a similar SDS-PAGE migration pattern as ERCC1. Interestingly, immunofluorescence experiments showed that this spurious 8F1 binding protein also localized in the nucleus. In this study, we have successfully identified PCYT1A, a nuclear membrane protein, as the 8F1 cross-reactive protein. We also found that PCYT1A exhibits similar biochemical and immunohistochemical properties as the spurious target discovered by Bhagwat et al. For example, PCYT1A shows a similar migration pattern as ERCC1 protein on SDS-PAGE gel even though it has a predicted molecular weight 10 kDa greater than ERCC1, and PCYT1A is localized exclusively in the nucleus by IHC. Alignment of the primary protein sequences showed no significant sequence homology between ERCC1 and PCYT1A, thus, it is likely that 8F1 recognizes a common conformational epitope on these two proteins. Although the 8F1 antibody binds equally well with ERCC1 or PCYT1A protein, there is no evidence that these two proteins share any functional relationship in development of drug resistance of cisplatin-based chemotherapy. Obviously, if a pathologist chose to use 8F1 antibody for ERCC1 protein expression evaluation, a potentially confounded result would be generated.
It is without question that high specificity is the pre-requisite for any antibody to be used for clinical diagnosis. Our data with 8F1 demonstrated that even a monoclonal antibody might not be mono-specific. Therefore, it is very critical to evaluate the specificity for every antibody to be utilized clinically. Scientists have spent years working to develop technologies to evaluate antibody specificity but we still do not have a platform that can address this question universally. At this stage, Western blot is the most commonly used approach to evaluate antibody specificity . A single WB band at the right molecular weight is considered the primary criteria for antibody specificity. However, there are still a number of intrinsic issues that could lead to the wrong conclusion regarding antibody specificity. For example, the SDS-PAGE gel migration patterns for certain proteins, especially membrane proteins, do not always align well with their theoretically predicted molecular weights . In another case, if a cross-reactive protein co-migrates with the authentic target on SDS-PAGE gel, it will be extremely difficult for us to distinguish them. For some target genes, the expression may be regulated in a highly temporal and spatial manner making an assessment by W. blotting uninformative from a clinical perspective [37, 38]. Therefore, it is difficult to find a single type of cell line or tissue to evaluate antibody specificity in an unbiased way. The ultimate goal for antibody specificity testing is to evaluate whether a particular antibody will only bind to its authentic target, but not with other proteins within the human genome. Therefore, under the dream scenario, this antibody should be tested against every single human protein in the genome, which could be impossible to carry out practically. The protein microarray chip with its high throughput capacity provides a perfect technology platform. Since each protein target is spotted and annotated at a specific site on the chip, tens of thousands of target specific immuno-reactions can be performed simultaneously. In this study, we utilized OriGene VERIFY™ overexpression lysates collection for protein microarray chip generation. One of the major concerns is whether the endogenous protein expression within HEK293T cells will potentially create a background signal that masks the specific target on each crude lysate spot. According to our data, we found that the protein expression level for most of the exogenously expressed recombinant proteins is hundreds or even thousands times higher than their endogenous counterparts (data not shown). This is partly due to the utilization of a strong CMV promoter to boost the transcription level and to the presence of large T antigen within HEK293T that permits amplification of the transfected plasmids containing an SV40 replication origin. We also have data showing that a large number of membrane proteins, which are nearly impossible to purify, can be produced in large quantities in HEK293T cells and extracted efficiently under our lysis buffer conditions (data not shown). In this study, our experimental data clearly demonstrate that this chip is a perfect tool for antibody specificity testing. We believe that every potential diagnostic or therapeutic antibody should be evaluated on a genome-wide coverage protein microarray chip for mono-specificity before application in a clinical setting.
In conclusion, we developed a high density protein microarray chip for antibody specificity evaluation. With this technology, we screened a number of commonly used anti-ERCC1 antibodies and discovered that 8F1, the most cited monoclonal antibody in clinical studies, is not specific. This antibody not only reacts with its authentic target, but also cross-reacts with PCYT1A, a nuclear membrane protein with no clinical implication on Cisplatin drug resistance. In the meantime, we also generated two IHC mouse monoclonal antibodies with exclusive target specificity, which were proofed by the high density protein microarray chip platform. Antibodies from these two clones, 2E12 and 4F9, also demonstrated superior performance on IHC application with NSCLC patient FFPE tissue sections.
This research was partially supported by an NIH SBIR grant 1R43GM093450-01 to D.M. We thank OriGene TrueORF cloning team for the collection of human full length cDNA clones, lysate production team for the collection of overexpression lysates of human cDNA genes, Wei Fu for performing the 8F1 antibody serial dilution experiments and Lori Mull and Jian Chen for comments on the manuscript.
- Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O’Connell M, Shepherd FA, Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001, 19 (6): 1734-1742.Google Scholar
- Coleman MH, Bueno R: Role of adjuvant chemotherapy in NSCLC (stages I to III). Surg Oncol Clin N Am. 2011, 20 (4): 757-767. 10.1016/j.soc.2011.07.011.View ArticleGoogle Scholar
- Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005, 4 (4): 307-320. 10.1038/nrd1691.View ArticleGoogle Scholar
- Hanigan MH, Devarajan P: Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy. 2003, 1: 47-61.Google Scholar
- Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73 (9): 994-1007. 10.1038/sj.ki.5002786.View ArticleGoogle Scholar
- Miller RP, Tadagavadi RK, Ramesh G, Reeves WB: Mechanisms of Cisplatin nephrotoxicity. Toxins. 2010, 2 (11): 2490-2518. 10.3390/toxins2112490.View ArticleGoogle Scholar
- Uehara T, Yamate J, Torii M, Maruyama T: Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics. J Toxicol Pathol. 2011, 24 (2): 87-94. 10.1293/tox.24.87.View ArticleGoogle Scholar
- Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007, 356 (8): 800-808. 10.1056/NEJMoa065411.View ArticleGoogle Scholar
- Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006, 355 (10): 983-991. 10.1056/NEJMoa060570.View ArticleGoogle Scholar
- Geiger S, Schlemmer M, Heinemann V, Stemmler HJ: Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anticancer Drugs. 2010, 21 (9): 799-804. 10.1097/CAD.0b013e32833dbbfe.View ArticleGoogle Scholar
- Rahn JJ, Adair GM, Nairn RS: Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen. 2010, 51 (6): 567-581.Google Scholar
- Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000, 60 (9): 1305-1313. 10.1016/S0006-2952(00)00441-X.View ArticleGoogle Scholar
- Martin LP, Hamilton TC, Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008, 14 (5): 1291-1295. 10.1158/1078-0432.CCR-07-2238.View ArticleGoogle Scholar
- Kirschner K, Melton DW: Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010, 30 (9): 3223-3232.Google Scholar
- Altaha R, Liang X, Yu JJ, Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004, 14 (6): 959-970.Google Scholar
- Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002, 8 (7): 2286-2291.Google Scholar
- Rosell R, Lord RV, Taron M, Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002, 38 (3): 217-227. 10.1016/S0169-5002(02)00224-6.View ArticleGoogle Scholar
- Arbogast S, Behnke S, Opitz I, Stahel RA, Seifert B, Weder W, Moch H, Soltermann A: Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. Appl Immunohistochem Mol Morphol. 2011, 19 (2): 99-105. 10.1097/PAI.0b013e3181f1feeb.View ArticleGoogle Scholar
- Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009, 69 (17): 6831-6838. 10.1158/0008-5472.CAN-09-1237.View ArticleGoogle Scholar
- Lima LM, de Souza LR, da Silva TF, Pereira CS, Guimaraes AL, de Paula AM, de Andrade Carvalho H: DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology. 2012, 60 (3): 489-496. 10.1111/j.1365-2559.2011.04062.x.View ArticleGoogle Scholar
- Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al: Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008, 14 (13): 4225-4231. 10.1158/1078-0432.CCR-07-4848.View ArticleGoogle Scholar
- Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, et al: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009, 20 (8): 1414-1419. 10.1093/annonc/mdp002.View ArticleGoogle Scholar
- Zajchowski DA, Karlan BY, Shawver LK: Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas. Mol Cancer Ther. 2012, 11 (2): 492-502. 10.1158/1535-7163.MCT-11-0746.View ArticleGoogle Scholar
- Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, et al: Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res. 2011, 17 (17): 5562-5572. 10.1158/1078-0432.CCR-11-0790.View ArticleGoogle Scholar
- Niedernhofer LJ, Bhagwat N, Wood RD: ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007, 356 (24): 2538-2540. author reply 2540-2541View ArticleGoogle Scholar
- Sugimoto H, Banchio C, Vance DE: Transcriptional regulation of phosphatidylcholine biosynthesis. Prog Lipid Res. 2008, 47 (3): 204-220. 10.1016/j.plipres.2008.01.002.View ArticleGoogle Scholar
- Agassandian M, Chen BB, Schuster CC, Houtman JC, Mallampalli RK: 14-3-3zeta escorts CCTalpha for calcium-activated nuclear import in lung epithelia. FASEB J. 2010, 24 (4): 1271-1283. 10.1096/fj.09-136044.View ArticleGoogle Scholar
- Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM: Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol. 2010, 97 (2): 352-359. 10.1016/j.radonc.2010.08.019.View ArticleGoogle Scholar
- Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, et al: Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study. Gynecol Oncol. 2012, 125 (2): 421-426. 10.1016/j.ygyno.2012.01.008.View ArticleGoogle Scholar
- Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983, 305 (5934): 537-540. 10.1038/305537a0.View ArticleGoogle Scholar
- Jantscheff P, Winkler L, Karawajew L, Kaiser G, Bottger V, Micheel B: Hybrid hybridomas producing bispecific antibodies to CEA and peroxidase isolated by a combination of HAT medium selection and fluorescence activated cell sorting. J Immunol Methods. 1993, 163 (1): 91-97. 10.1016/0022-1759(93)90243-Z.View ArticleGoogle Scholar
- Ridsdale R, Tseu I, Wang J, Post M: CTP:phosphocholine cytidylyltransferase alpha is a cytosolic protein in pulmonary epithelial cells and tissues. J Biol Chem. 2001, 276 (52): 49148-49155. 10.1074/jbc.M103566200.View ArticleGoogle Scholar
- Roth JA, Carlson JJ: Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2011, 12 (6): 393-401. 10.1016/j.cllc.2011.04.005.View ArticleGoogle Scholar
- Soltermann A, Kilgus-Hawelski S, Behnke S, Storz M, Moch H, Bode B: Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinform. 2011, 1: 25-10.1186/2043-9113-1-25.View ArticleGoogle Scholar
- Spurrier B, Washburn FL, Asin S, Ramalingam S, Nishizuka S: Antibody screening database for protein kinetic modeling. Proteomics. 2007, 7 (18): 3259-3263. 10.1002/pmic.200700117.View ArticleGoogle Scholar
- Goshima N, Kawamura Y, Fukumoto A, Miura A, Honma R, Satoh R, Wakamatsu A, Yamamoto J, Kimura K, Nishikawa T, et al: Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods. 2008, 5 (12): 1011-1017. 10.1038/nmeth.1273.View ArticleGoogle Scholar
- Mulder J, Bjorling E, Jonasson K, Wernerus H, Hober S, Hokfelt T, Uhlen M: Tissue profiling of the mammalian central nervous system using human antibody-based proteomics. Mol Cell Proteomics. 2009, 8 (7): 1612-1622. 10.1074/mcp.M800539-MCP200.View ArticleGoogle Scholar
- Uhlen M, Ponten F: Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics. 2005, 4 (4): 384-393. 10.1074/mcp.R500009-MCP200.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.